Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials Eli Lilly and Company TRIUMPH-2 and TRIUMPH-3 topline results Lilly reports positive topline results from two more pivotal Phase 3 trials, bringing the number of Phase 3 studies it describes as positive to five
The peptide functions as a non-selective agonist of melanocortin receptors, specifically MC1R, MC3R, MC4R, and to a lesser extent MC5R
doi: 10.1056/NEJMoa1607141 29 PratleyREArodaVRLingvayILdemannJAndreassenCNavarriaAet al
Question 1: How will this work with my current treatment plan and/or medications
US$ 23.97
US$ 21.37
US$ 24.15
US$ 25.93
US$ 27.04
US$ 20.80
US$ 29.48
